Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study
Sign Up to like & getrecommendations! Published in 2020 at "Expert Review of Anti-Infective Therapy"
DOI: 10.1080/14787210.2020.1800453
Abstract: ABSTRACT Background Tocilizumab, an inhibitor of the interleukin-6 receptor, may decrease the inflammatory response and control the symptoms of severe coronavirus disease 2019 (COVID-19), but the evidence is scarce. Methods This retrospective study included patients… read more here.
Keywords: patients severe; tocilizumab patients; patients within; clinical status ... See more keywords
A Multicentre, Large-Scale, Observational Study of Tocilizumab in Patients with Takayasu Arteritis in Japan: The ACT-Bridge Study.
Sign Up to like & getrecommendations! Published in 2022 at "Modern rheumatology"
DOI: 10.1093/mr/roac099
Abstract: OBJECTIVES We evaluated the real-world tolerability and effectiveness of tocilizumab in Japanese patients with Takayasu arteritis (TAK). METHODS Patients with TAK who had not received tocilizumab in the previous 6 months were enrolled in ACT-Bridge,… read more here.
Keywords: takayasu arteritis; patients takayasu; observational study; act bridge ... See more keywords
Tocilizumab in patients with adult-onset Still’s disease refractory to glucocorticoid treatment
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-214635
Abstract: I was pleased to read the article by Kaneko and colleagues1 on the efficacy and safety of tocilizumab in patients with adult-onset Still’s disease, because the current information on its biologic efficacy has been mainly… read more here.
Keywords: onset still; adult onset; disease refractory; tocilizumab patients ... See more keywords